"I think Erbitux is more of a treatment than we've given it credit for, " Venook says.

FORBES: ImClone's Next Hurdles: Cost And Competition

"With all of these agents, the real problem is that patients benefit, but it's really only 10% or 20% of patients who benefit, " says Venook.

FORBES: Puncturing The ImClone Hype

Venook will be heading up a clinical trial with Erbitux and chemotherapy in previously untreated patients for Bristol and ImClone, and that could help further answer questions about the drug's effectiveness.

FORBES: Puncturing The ImClone Hype